EDT Spectral Medical

Spectral Medical to Present at the H.C. Wainwright Virtual BioConnect Conference

Spectral Medical to Present at the H.C. Wainwright Virtual BioConnect Conference

TORONTO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), today announced that it will be presenting at the H.C. Wainwright Virtual BioConnect Conference, being held January 11 – 14, 2021. Dr. Paul Walker, President and CEO, and Chris Seto, COO and CFO of Spectral Medical Inc. will be hosting the presentation.

About Spectral

Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.

PMX is approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 200,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 330,000 patients are diagnosed with severe sepsis and septic shock in North America each year.

Spectral, through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new proprietary platform, “SAMI”, targeting the renal replacement therapy (“RRT”) market.  Dialco is also seeking regulatory approval for in-home use of “DIMI” which is based on the same RRT platform, but will be intended for home hemodialysis use.  “DIMI” recently received its FDA 510k clearance for use in hospital and clinical settings.

Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit .

Contact:

Dr. Paul Walker 

President and CEO 

Spectral Medical Inc.

416-626-3233 ext. 2100 

Mr. Chris Seto 

COO & CFO 

Spectral Medical Inc.

416-626-3233 ext. 2004 

 
Ali Mahdavi

Capital Markets & Investor

Relations

416-962-3300

   
David Waldman/Natalya Rudman

US Investor Relations

Crescendo Communications, LLC

212-671-1020

  



EN
11/01/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spectral Medical

 PRESS RELEASE

Spectral Medical Provides Update on PMA Submission Timing for PMX-20R

Spectral Medical Provides Update on PMA Submission Timing for PMX-20R TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the timing of its Premarket Approval (“PMA”) submission to the U.S. Food and Drug Administration (“FDA”) for its hemoadsorption device to treat endotoxic septic shock. Following recent interaction with the FDA, the Company now expects to submit its PMA around the end of April to mid-May 2026, com...

 PRESS RELEASE

Spectral Medical Announces Third Quarter 2025 Financial Results and Pr...

Spectral Medical Announces Third Quarter 2025 Financial Results and Provides Corporate Update PMA submission targeted for Q1 2026 following positive Tigris results and ongoing FDA interactionsCompany to host Corporate Update call on Wednesday, December 10, 2025 TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the third quarter and provided a corporate update. The third quarter of 2025 marke...

 PRESS RELEASE

Spectral Medical Inc. Files Base Shelf Prospectus and Revised AIF

Spectral Medical Inc. Files Base Shelf Prospectus and Revised AIF TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, announced that it has filed a final short form base shelf prospectus (the “Base Shelf Prospectus”) with the securities regulatory authorities in each of the provinces of Canada, except Québec (the “Securities Regulators”) on September 26, 2025 (the “Effective Date”). The Base Shelf Prospectus allows Spectral to qualify the d...

 PRESS RELEASE

Spectral Medical Announces Publication of EDEN Observational Study

Spectral Medical Announces Publication of EDEN Observational Study New Study Strengthens Rationale for Spectral’s PMX Therapy by Defining Endotoxic Septic Shock (ESS) as the Highest-Risk Patient Group TORONTO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today highlighted newly published findings in Critical Care Explorations that define endotoxic septic shock (“ESS”) as a distinct and deadly form of septic shock. The prospective, multicent...

 PRESS RELEASE

Spectral Medical Sponsors Unite for Sepsis Symposium, Chicago Septembe...

Spectral Medical Sponsors Unite for Sepsis Symposium, Chicago September 8 – 9, 2025 Company to present at session titled “Personalizing Sepsis Treatment” TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its sponsorship of the Unite for Sepsis Symposium, taking place September 8 – 9, 2025, in Chicago, Illinois. The Company also announced that Debra Foster, Clinical Consultant at Spectral Medical, will participate in a feat...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch